Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +35.93%
#2 Siren Siren +30.58%
#3 Purr Purr +28.58%
#4 OriginTrail OriginTrail +23.69%
#5 ApeX ApeX +17.69%
#6 UnifAI Network UnifAI Network +16.61%
#7 Wrapped XPL Wrapped XPL +16.15%
#8 Plasma Plasma +16.04%
#9 Unit Plasma Unit Plasma +16.04%
#10 Pendle Pendle +15.57%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.

Senhwa Biosciences, Inc.

6492
Kedudukan dalam Saham #21774
Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and... Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and headquartered in New Taipei City, Taiwan, specializes in advancing novel drugs and targeted therapeutic agents. The firm is actively progressing several clinical programs. Its compound CX-5461 is undergoing various investigations, including a Phase I, open-label study assessing dose escalation, safety, pharmacokinetics, and pharmacodynamics of its intravenous administration in individuals with advanced blood cancers. CX-5461 is also in a Phase I trial for solid cancerous growths, as well as a Phase Ib expansion study focusing on solid tumors characterized by BRCA2 and/or PALB2 genetic mutations. Furthermore, CX-5461 is being evaluated in a Phase I trial alongside pidnarulex and talazoparib for patients battling metastatic castration-resistant prostate cancer. Beyond CX-5461, Senhwa is also developing several variations of CX-4945. CX-4945-CCA is participating in a Phase I/II clinical investigation, combined with gemcitabine, for treating cholangiocarcinoma. CX-4945-BCC is the subject of a Phase I, multi-center, open-label study, examining its safety and pharmacodynamic profile when administered orally twice daily to patients with advanced basal cell carcinoma. The company's CX-4945-MB compound is being explored in a Phase I/II and surgical study, led by a pediatric brain tumor consortium, for the management of recurrent SHH medulloblastoma. Lastly, CX-4945-AV06 is currently in a Phase II, double-blind, randomized, controlled study, designed to evaluate its safety and effectiveness in hospitalized adults afflicted with COVID-19.
Harga Saham
$1.11
Disegerakkan terakhir: 2026-08-21
Modal Pasaran
$100.55M
Perubahan (1 hari)
-7.69%
Perubahan (1 tahun)
-7.17%
Negara
TW
Perdagangan Senhwa Biosciences, Inc. (6492)

Kategori

Healthcare
Sejarah harga saham bagi Senhwa Biosciences, Inc. (6492)
Harga penutupan tertinggi: $1.20 pada 2026-08-01

Harga penutupan terendah: $3.18 pada 2014-12-01
Sejarah harga saham Senhwa Biosciences, Inc. dari 2014 hingga 2026
Prestasi harga saham tahunan
Tahun Prestasi
2026 (TTM) 9.09%
2025 -0.30%
2024 -22.02%
2023 -15.51%
2022 -44.72%
2021 -53.30%
2020 275.09%
2019 -9.86%
2018 3.54%
2017 -60.65%
2016 1.24%
2015 74.07%
2014 0.00%
Harga saham bagi syarikat atau pesaing serupa
Syarikat Harga saham Perubahan 1thn% Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $547.71 38.62%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.04K 58.06%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $145.75 437.43%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $118.70 -15.60%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $770.19 8.98%
CH